- Home
- THR vs AUPH Comparison
THR vs AUPH Comparison
Compare THR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THR
- AUPH
- Stock Information
- Founded
- THR 1954
- AUPH 1993
- Country
- THR United States
- AUPH Canada
- Employees
- THR N/A
- AUPH N/A
- Industry
- THR Industrial Machinery/Components
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- THR Energy
- AUPH Health Care
- Exchange
- THR Nasdaq
- AUPH Nasdaq
- Market Cap
- THR 887.4M
- AUPH 999.8M
- IPO Year
- THR 2011
- AUPH 1999
- Fundamental
- Price
- THR $28.56
- AUPH $8.05
- Analyst Decision
- THR Strong Buy
- AUPH Strong Buy
- Analyst Count
- THR 1
- AUPH 2
- Target Price
- THR $38.00
- AUPH $11.50
- AVG Volume (30 Days)
- THR 115.7K
- AUPH 966.4K
- Earning Date
- THR 05-28-2025
- AUPH 05-12-2025
- Dividend Yield
- THR N/A
- AUPH N/A
- EPS Growth
- THR N/A
- AUPH N/A
- EPS
- THR 1.37
- AUPH 0.04
- Revenue
- THR $491,781,000.00
- AUPH $235,133,000.00
- Revenue This Year
- THR $0.92
- AUPH $11.86
- Revenue Next Year
- THR $8.63
- AUPH $24.96
- P/E Ratio
- THR $20.63
- AUPH $203.75
- Revenue Growth
- THR 0.47
- AUPH 33.97
- 52 Week Low
- THR $23.05
- AUPH $4.98
- 52 Week High
- THR $35.93
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- THR 64.52
- AUPH 54.99
- Support Level
- THR $27.21
- AUPH $7.89
- Resistance Level
- THR $28.83
- AUPH $8.21
- Average True Range (ATR)
- THR 0.79
- AUPH 0.22
- MACD
- THR 0.42
- AUPH 0.02
- Stochastic Oscillator
- THR 97.67
- AUPH 69.84
About THR Thermon Group Holdings Inc.
Thermon Group Holdings Inc is a United States-based company that provides engineered thermal solutions for process industries. The company's product portfolio comprises electric heat tracing cables, steam tracing components, tubing bundles, and instrument and control products, as well as complementary product lines. It also provides turnkey services and design and engineering services. The company's customers include large engineering, procurement, and construction companies; oil and gas companies; commercial subcontractors; electrical component distributors; and others. The company has a presence, with the United States, Canada, and Europe being its top three markets and contributing the majority of its sales.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.